J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
L u m i l i x i m a b
5 l a n g u a g e s
● ا ل ع ر ب ي ة ● E s p a ñ o l ● F r a n ç a i s ● I t a l i a n o ● T i ế n g V i ệ t
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Lumiliximab is an IgG1k monoclonal antibody that targets CD23 . It acts as an immunomodulator [1] orphan drug status and fast track designation by the FDA.[2]
It was investigated in Phase II/III clinical trials for the treatment of chronic lymphocytic leukemia .[3] [4] allergic asthma . The drug is a chimeric antibody from Macaca irus Homo sapiens [1]
Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen .
Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.[2] [5]
References
[ edit ]
^ Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, et al. (January 2010). "Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia" . Blood . 115 (3 ): 489–95. doi :10.1182/blood-2009-08-237727 . PMC 2810983 PMID 19843887 .
^ Clinical trial number NCT00801060 ClinicalTrials.gov
^ Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, et al. (November 2014). "A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia" . British Journal of Haematology . 167 (4 ): 466–77. doi :10.1111/bjh.13061 hdl :2318/1577053 PMID 25130401 . S2CID 25789983 .
t
e
Intracellular
Intracellular
Extracellular
Unsorted
t
e
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Lumiliximab&oldid=1193763495 " C a t e g o r i e s : ● D r u g s n o t a s s i g n e d a n A T C c o d e ● M o n o c l o n a l a n t i b o d i e s ● M o n o c l o n a l a n t i b o d y s t u b s ● A n t i n e o p l a s t i c a n d i m m u n o m o d u l a t i n g d r u g s t u b s H i d d e n c a t e g o r i e s : ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n i s d i f f e r e n t f r o m W i k i d a t a ● A r t i c l e s w i t h c h a n g e d C A S N o i d e n t i f i e r ● C h e m i c a l s t h a t d o n o t h a v e a C h e m S p i d e r I D a s s i g n e d ● A r t i c l e s w i t h o u t E B I s o u r c e ● A r t i c l e s w i t h o u t K E G G s o u r c e ● A r t i c l e s w i t h o u t I n C h I s o u r c e ● D r u g s w i t h n o l e g a l s t a t u s ● D r u g b o x e s w h i c h c o n t a i n c h a n g e s t o v e r i f i e d f i e l d s ● D r u g b o x e s w h i c h c o n t a i n c h a n g e s t o w a t c h e d f i e l d s ● D r u g s t h a t a r e a m o n o c l o n a l a n t i b o d y ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 5 J a n u a r y 2 0 2 4 , a t 1 4 : 1 8 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
N
Y (what is this?) (verify)
